-
OPTIMIZING ACCESS TO ACORAMIDIS IN THE UNITED STATES: THE ROLE OF PATIENT ACCESS LIAISONS (PALS) IN TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM)
Mar 18, 2026, 21:38 PM -
ACCELERATING EVIDENCE GENERATION: LEVERAGING LLMS FOR FULL-TEXT STUDY SELECTION
Mar 18, 2026, 21:38 PM -
BEYOND COST-EFFECTIVENESS: ADAPTING THE ISPOR VALUE FLOWER FOR MULTI-CRITERIA DECISION ANALYSIS IN KAZAKHSTAN
Mar 18, 2026, 21:38 PM -
PREDICTING OVERALL SURVIVAL FROM SURROGATE ENDPOINTS: A TWO-STAGE BAYESIAN META-ANALYTIC SURROGACY FRAMEWORK INCORPORATING RECOVERED INDIVIDUAL-LEVEL DEPENDENCE INFORMATION
Mar 18, 2026, 21:38 PM -
CHARACTERIZING ONCOLOGY PATIENT JOURNEYS AND HEALTH STATE TRANSITIONS USING A DATA-DRIVEN MARKOV TRANSITION MATRIX IN LARGE-SCALE ELECTRONIC HEALTH RECORDS
Mar 18, 2026, 21:38 PM -
IMPACT OF COMORBID DEPRESSION ON INSULIN INITIATION AND CARDIOVASCULAR OUTCOMES AMONG PATIENTS WITH TYPE 2 DIABETES MELLITUS: A MULTINATIONAL OHDSI COHORT STUDY
Mar 18, 2026, 21:38 PM -
COST-EFFECTIVENESS OF TRASTUZUMAB REZETECAN VERSUS TRASTUZUMAB DERUXTECAN FOR THE SUBSEQUENT-LINE TREATMENT OF ADVANCED HER2-MUTANT NON-SMALL-CELL LUNG CANCER: APPLICATION OF A MATCHING-ADJUSTED INDIRECT COMPARISON
Mar 18, 2026, 21:38 PM -
COMPARATIVE EFFECTIVENESS AND HARMS OF SUSTAINED STATIN THERAPY AMONG YOUNG ADULTS
Mar 18, 2026, 21:38 PM -
ADOPTION AS A MISSING LINK IN HEOR: EVIDENCE MAPPING OF HEALTHCARE INNOVATION UPTAKE
Mar 18, 2026, 21:38 PM -
A MULTI-COUNTRY RETROSPECTIVE CHART REVIEW OF TREATMENT PATTERNS AND RESOURCE USE IN PATIENTS WITH NEWLY DIAGNOSED PH-NEGATIVE B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA UNDERGOING FIRST-LINE CONSOLIDATION THERAPY
Mar 18, 2026, 21:38 PM -
ECONOMIC AND HUMANISTIC BURDEN AMONG U.S. ADULTS WITH NONHODGKIN LYMPHOMA: ANALYSIS OF NATIONAL SURVEY DATA
Mar 18, 2026, 21:38 PM -
USER EVALUATION OF AN AGENTIC AI ASSISTANT FOR REAL-WORLD EVIDENCE FEASIBILITY ANALYSIS
Mar 18, 2026, 21:38 PM -
FRACTURE INCIDENCE AND ECONOMIC BURDEN OF FEMALE PATIENTS WITH OSTEOPOROSIS AT VERY HIGH RISK OF FRACTURE IN CHINA
Mar 18, 2026, 21:38 PM -
STRATEGIC COMPARISON OF CENTER FOR PHARMACOECONOMICS AND INSTITUTE FOR CLINICAL AND ECONOMIC REVIEW ECONOMIC EVALUATIONS
Mar 18, 2026, 21:38 PM -
THE BUDGET IMPACT OF TUMOR-TREATING FIELDS PLUS GEMCITABINE AND NAB-PACLITAXEL FOR FRONT-LINE TREATMENT OF LOCALLY ADVANCED PANCREATIC CANCER
Mar 18, 2026, 21:38 PM -
TRENDS AND POSTMARKETING OUTCOMES OF ACCELERATED APPROVALS (AAS) IN FDA NEW DRUG APPLICATIONS AND BIOLOGIC LICENSE APPLICATIONS (NDAS/BLAS) FROM 1992-2025
Mar 18, 2026, 21:38 PM -
COST-EFFECTIVENESS OF ARTIFICIAL INTELLIGENCE (AI)-ASSISTED BRAIN MAGNETIC RESONANCE IMAGING (MRI) INTERPRETATION IN ADVANCED LUNG CANCERS
Mar 18, 2026, 21:38 PM -
COMPARATIVE EFFECTIVENESS OF PHARMACOLOGICAL TREATMENTS FOR STABLE CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN THE CHINESE POPULATION: A BAYESIAN NETWORK META ANALYSIS
Mar 18, 2026, 21:38 PM -
THE COST-EFFECTIVENESS OF INCLUSION OF JERYL LYNN MUMPS VACCINE IN THE MEASLES-RUBELLA ROUTINE IMMUNISATION SCHEDULE AMONG CHILDREN IN INDIA
Mar 18, 2026, 21:38 PM -
TRENDS IN LDL CHOLESTEROL LEVELS AMONG MEDICARE ADVANTAGE BENEFICIARIES: 2015-2024
Mar 18, 2026, 21:38 PM
